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Yeast: bridging the gap between phenotypic and biochemical assays for high-
throughput screening 
 
Abstract:  
 
Introduction:  
Both in vitro biochemical and phenotypic assay platforms have clear limitations in high 
throughput screening (HTS) for drug discovery. The use of genetically tractable model yeast 
as a vehicle for target-based HTS overcomes many of these by allowing the identification of 
on-target compounds that function within a eukaryotic cellular context. 
 
Areas covered: 
In this Special Report, the use of yeast-based assays in HTS is discussed with reference to 
the various platforms that have been utilized over the past 20 years. The specific issues 
considered are the necessity to employ counter and secondary screening approaches to 
ensure the on-target activity of hits, and the recent developments in detection systems that 
have facilitated miniaturization and ultra-HTS. 
 
Expert opinion:  
The demonstrable possibilities of optimizing yeast-based HTS, coupled with the 
demonstration of utility in an industrial setting, shows that these platforms have the potential 
to bridge the gap between phenotypic and biochemical assays for HTS. 
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1. Introduction: 
High throughput screening (HTS) facilitates the analyses of vast numbers of compounds 
(≥100,000/day) for biological activity, an approach central to modern drug discovery efforts. 
HTS assays formats can, in general, in divided into two categories: in vitro biochemical and 
cell-based, phenotypic assays. The former are often simpler and more specific, whereas cell-
based phenotypic assays can be more challenging but provide cellular context [1]. 
For the automated HTS required to achieve true high content screening, all assays must be 
as simple as possible. For example, in vitro biochemical assays must produce a readily 
detectable and quantifiable signal (fluorescence, radiochemical etc) without complex 
substrate-product separation. This necessitates the isolation of pure, soluble and 
enzymatically active protein, clearly these requirements can be major obstacles [2, 3]. In 
contrast, cell-based phenotypic HTS platforms do not require target protein purification nor 
any knowledge of the target or targets, and compound activity is established in a cellular 
context that mirrors the in vivo scenario. For example, the necessity for a compound to cross 
membrane barriers to reach an intracellular target, thus predicting those compounds least 
likely to exhibit problems with stability or solubility in vivo and fast-tracking drug-like entities 
for further development. However, these advantages can also be detrimental. For example, 
compounds that fail to cross membrane barriers and reach the target could represent 
promising early stage hits, and their loss precludes further development. In addition, the non-
target-based phenotypic readout requires that target deconvolution is approached a posteriori 
to facilitate rational development of compound hits [2, 3].  
In summary, both approaches have distinct challenges which are summarized in Table 1.  
However, to best reflect the physiological context in which a compound has an effect, cell-
based assays have obvious advantages [4]. Engineering the cell to provide a target specific 
readout is possible, thereby combining the advantages of both in vitro biochemical and cell-
based, phenotypic assays. However, target eukaryotic cells can be difficult and expensive to 
culture and genetically manipulate [5], in addition the process redundancy found in complex 
systems can cofound the readout of HTS for a specific inhibitor [6]. Therefore, whilst cell-
based systems clearly provide some significant advantages compared with conventional 
target-based in vitro approaches, their use is not without limitations.  
Yeast, particularly Saccharomyces cerevisiae,  but also Schizosaccharomyces pombe, have 
been long established as relatively simple, tractable and highly characterised model 
eukaryotes [7]. Yeast benefit from a highly developed genetic tool kit and are fast growing 
(doubling time ~90 minutes) in simple, low-cost (liquid or solid) media. Such characteristics 
make S. cerevisiae and S. pombe ideal for antifungal HTS [8]. However given that many 
  
cellular pathways are conserved in yeast and other eukaryotes (e.g. humans) these model 
cells can be easily engineered for the analyses of  orthologous functions [9]. For example, the 
use of the yeast two hybrid systems has been utilized to identify inhibitors of protein-protein 
interactions [10, 11]. However, the application of this technology for drug discovery has been 
relatively limited. In the following sections I will focus on the wider use of yeast-based platforms 
designed to identify inhibitors of protein function. The predominant platforms have been 
previously described and illustrated [2, 3], and in the following sections the contribution of 
yeast to HTS and drug discovery will be further discussed with reference to the available 
literature (Table 2, in chronological order) and the future perspectives considered. 
 
2. Yeast HTS platforms 
2.1 Lethal expression 
Given the highly developed genetic tool kit available to modify the yeast genome and express 
axenic proteins, both S. cerevisiae and S. pombe have been successfully engineered into 
reporter systems that have been utilized in HTS. For example, expression of the influenza 
virus ion-channel forming protein in S. cerevisiae is lethal [12]. The expression of pro-apoptotic 
HIV-1 protein Vpr is similarly lethal to the fission yeast S. pombe [13].  For both cases, this 
lethal phenotype has been utilized to identify molecules that rescue the yeast, i.e. inhibit 
orthologous protein function. Lethal expression has also been used in yeast-based screens 
for modulators of human proteins [4, 6]. For example, the human kinase p38a [14] and 
phosphatidylinositol 3-kinase (PI3K) [15] are both associated with oncogenesis (and a 
plethora of other diseases, Table 2) and their expression is toxic to S. cerevisae [16, 17], as 
is the expression of a-synuclein (a-syn) associated with Parkinson’s disease [18, 19, 20]. 
Similarly, recent work described an S. cerevisiae lethal expression platform in which yeast 
deficient in uridine transport were made susceptible to toxic 5-FUrd by the expression of 
Nucleoside Transporter 1 from the malaria parasite Plasmodium falciparum. These were then 
utilized in HTS to identify antimalarial compounds [21]. Importantly, in all phenotypic rescue 
assays the possibility of generically toxic false positives is removed greatly simplifying the 
generation and interpretation of data.  
 
2.2 Transactivation 
Lethal expression-based platform readout is reliant on positive growth changes in response 
to the direct chemical modulation of the target protein. However, given the extreme genetic 
tractability of both S. cerevisiae and S. pombe it is possible to engineer these model yeast to 
provide an indirect HTS readout through transactivation. Several examples have been 
reported [22, 23] (Table 2), but the most extensively described and HTS utilized example of a 
  
yeast transactivation platform has been directed towards the discovery of mammalian 
phosphodiesterase (PDE) inhibitors [24, 25, 26, 27, 28]. The approximately 100, tissue 
specific, mammalian PDE isoforms all catalyze the conversion of cAMP and cGMP to the 
cyclic secondary messengers 5’AMP and 5’GMP. Given the tissue specificity of many of these 
isoforms, selective modulation has been recognized as having therapeutic potential for a wide 
range of human diseases [29, 30] (Table 2). S. pombe can tolerate deletion of adenylate 
cyclase (cyr1) and PDE (csg2).  In their absence, exogenous cAMP or cGMP activates Protein 
Kinase A (PKA) and ura4 expression from an introduced selectable marker is repressed. In 
the absence of ura4 expression, the yeast can grow in the presence of 5-fluoroorotic acid 
(5FOA), which is converted to toxic fluoroorotidine monophosphate in the presence of URA4 
[28, 31]. However, expression of yeast (Cyr1) or a mammalian PDE facilitated the conversion 
of cAMP or cGMP to 5’AMP or 5’GMP, leading to ura4 expression and 5FOA sensitivity. 
Inhibition of PDE function rescued growth and the system has been formatted into a positive 
selection HTS used to screen libraries >200k in size [24, 25, 26, 27, 28]. To ensure specificity 
against single or small numbers of PDE isoforms screening against yeast expressing different 
isoforms can be undertaken, so called counter screening. Using this approach, many of the 
hits were demonstrated to be specific for one or more PDE isoforms [24, 25, 26, 27, 28].  
Again, like the lethal expression platforms, these phenotypic rescue assays reduce the 
likelihood of false positive hits. 
 
2.3 Substitution 
Despite the advantages (e.g. reducing false positives) of lethal expression and transactivation 
platforms, the majority of reported yeast-based HTS have relied on the simple substitution of 
an essential yeast function with the orthologue from the organism of interest. Of course, this 
is dependent of the conservation of protein function between the yeast and an often distantly 
related eukaryote. This approach has been widely used in HTS of mammalian targets [9]. For 
example, mutant S. cerevisiae complemented by expression of a human potassium channel 
protein (Kir2.1) was formatted into an HTS assay where inhibition at low but not high 
potassium was scored as a hit [32].  Similarly, with a view to discovering hit compounds 
towards the treatment of obesity, human acetyl-CoA carboxylase 2 (AAC2) inhibitors were 
identified by HTS using mutant S. cerevisiae reliant on expression of human AAC2 [33]. More 
recently, a S. cerevisiae substitution platform was employed for HTS to identify inhibitors of 
human adenine nucleotide translocase 4 (ANT4), a target for cancer and cardiovascular 
disease amongst others [34]. In both cases, counter screening against yeast complemented 
with isoforms of the target (human AAC1 and ANT1, -2 and 3 respectively) ensured selectivity 
[33, 34].  
  
However, the first report of the use of a substitution platform in HTS was against the ornithine 
decarboxylase (ODC), a key regulatory enzyme in eukaryotic polyamine (PA) biosynthesis, 
from Haemonchus contortus, a nematode worm that is a major parasite of ruminants. Similar 
to above, the platform utilized a S. cerevisae ODC deficient mutant complemented by 
expression of the H. contortus orthologue [35]. Subsequently, recent years have seen most 
published activity using S. cerevisiae substitution platforms directed to enable HTS against 
parasitic proteins [2, 3]. For example, S. cerevisiae mutant yeast have been complemented 
by the expression of dihydrofolate reductase (DHFR), N-myristoyltransferase (NMT), 
phosphoglycerate kinase (PGK) and several other targets (Table 2) from protozoan and 
helminth parasites [36, 37, 38]. An S. cerevisiae substitution platform has also been used in 
HTS to identify inhibitors of the anti-leishmanial drug target inositol phosphorylceramide (IPC) 
synthase [39, 40, 41]. In this case, in the absence of a mammalian orthologue [42, 43, 44, 45], 
counter screening was performed against the mutant complemented with the yeast orthologue 
AUR1 [41] to remove off-target, generically cytotoxic compounds. 
 
3. Detection and sensitivity 
Many of the initial studies utilized agar plate-based assays to create reporter systems [46, 47, 
48, 49]. However, it is clear that the measurement of growth on agar plates can only be semi-
quantitative, even when colourimetric [46, 47]. Therefore, the majority of yeast-based HTS 
now establish growth in liquid culture in microtiter plates, via optical density, colourimetry, 
fluorimetry, or a combination of these [21]. The great advantage is that this liquid format is 
amenable to miniaturization from 96-well to 384-well, and even to 1536-well [41] plates (Table 
2). The vast majority of assays have used turbidity (measured via optical density) as a 
measure of liquid growth [2, 3], sometimes with measures to enhance sensitivity such as 
deletion of efflux pumps, to reduce expulsion of potential inhibitory compounds, and non-lethal 
disruption of the plasma membrane [16]. However, a fluorescent readout provides 
considerably greater sensitivity [50] and has been recently employed in yeast-based HTS. For 
example, Bilsland et al (2013) employed fluorescent tags to facilitate multiplexing, thus 
allowing compounds to be screened against protozoan DHFR, NMT or PGK (Table 2) 
simultaneously with the human orthologue in a single well of a 384-well plate [37]. More 
recently, fluorescein di-β-D-glucopyranoside (FDGlu; a highly sensitive substrate for the 
glucosidases found in the yeast cell wall) was utilized to measure yeast growth in a HTS 
campaign against the Leishmania IPC synthase. The sensitivity of this approach allowed the 
assay to be miniaturized into 1536-well plates for screening against 1.8M compounds [41], to 
date the only published example of a yeast-based ultra-HTS. 
 
  
4. Secondary assays 
A significant advantage of the transactivation and lethal expression platforms described above 
is that they rely upon positive selection, thus reducing the number of generically toxic false-
positive hits. In contrast, the negative selection employed in substitution assays necessitates 
counter screening in eliminate false-positives. However, despite this clear advantage, all 
yeast-based platforms have the inherent possibility of producing false-positive hits, for 
example due to inhibition of other elements within a biosynthetic pathway [2, 3]. Therefore, as 
with all HTS, secondary screens to ensure that the identified hits are on target are an essential 
tool is the discovery process. These can be in vitro enzymatic and/or cell-based assays. For 
example, some hits identified in the multiple HTS (3k to >200k compounds) using PDE 
transactivation 384-well platforms, demonstrated selective PDE inhibition and physiological 
activity (e.g. cAMP elevation) in secondary assays [24, 25, 26, 27, 28]. Similarly, the two (from 
40,000 compounds) p38a hits from the lethal expression assay both demonstrated activity in 
in vitro and in mammalian cell secondary assays [17], and two cyclic peptide hits identified as 
active against a-syn in yeast prevented dopaminergic neuron loss in a Caenorhabditis elegans 
Parkinson’s model [19]. 
In assays designed to identify anti-infectives, secondary assays often involve establishing 
activity against the pathogen. For example, of the specific hits identified by Bilsland et al (2013) 
in the multiplexed fluorescent S. cerevisiae substitution platform, 50% proved cytotoxic to the 
protozoan parasite Trypanosoma brucei in cellulo [37]. However, this did not directly prove 
that the target was attenuated, in other work approaches involving in vitro and cell-based 
assays have demonstrated that the anti-parasitic hits generated from yeast-based screens do 
actually hit the intended target [21, 38, 41].  
The necessity of the secondary assay approach, target directed and across both in vitro and 
in cellulo platforms, was illustrated very clearly in one of the very first yeast-based HTS 
campaigns from 1997 [35]. Klein et al identified a single, selective, compound following HTS 
and counter screening in conditions where the target, helminth ODC, is redundant. However, 
this hit failed to inhibit the target in vitro instead, perhaps, inhibiting a yeast enzyme involved 
in spermidine and spermine synthesis [35]. 
 
5. Conclusion: 
As discussed above, yeast-based screening methodologies offer considerable benefits for 
HTS towards drug discovery (Table 1). Using their genetic tool box, yeast-based assays that 
facilitate a target-directed approach within a eukaryotic cell environment can be engineered 
to bridge the gap between phenotypic and biochemical assays for HTS. Such yeast-based 
  
assays are robust (Z-factor >0.5 [13, 16, 26, 31, 41]) and cost effective - using simple “mix 
and measure” approaches with output measured by monitoring cell growth in liquid media. 
Although most of those reported achieve this via optical density, more recent yeast-based 
HTS has employed fluorometric responses [21, 36, 37, 38, 41]. This has enabled 
miniaturization and high content screening using 384-well [21, 36, 37, 38] and, recently 1536-
well [41] platforms.  
Although yeast-based screens have limitations (Table 1), the capacity for ultra-HTS of millions 
of compounds against a target in a eukaryotic cellular context, when allied with necessary 
counter and secondary screens, makes yeast a promising tool for the discovery of drug-like 
hit compounds.  
 
Expert opinion: 
The capacity to screen for specific target inhibition in a manipulable and well-controlled 
eukaryotic cellular context, meaning that yeast-based HTS combines many of the advantages 
of conventional in vitro biochemical and phenotypic screening approaches (Table 1). The use 
of a relatively simple eukaryotic vehicle also reduces many of the confounding effects caused 
by biological pathway redundancies in higher organisms. However, the since the first reported 
yeast-based HTS in 1995 [12] less than 30 (many iterative) such campaigns have been 
published in the scientific literature (Table 2), a rate of little more than 1 per year. This relatively 
low level of visible activity is a limitation on development of these platforms, which of course 
have challenges such as the presence of a thick cell wall and highly expressed efflux pumps 
which reduce assay sensitivity. Although, genetic and chemical approaches to overcome 
these have been employed [16, 51] their use, and so validation, is limited. Furthermore, the 
use of sensitive fluorescent approaches and miniaturization towards ultra-HTS is recent and 
only deployed for a limited number of targets [21, 36, 37, 38, 41].  
This lack of evidential research explains why no record of lead to hit drug discovery 
programmes stemming from yeast-based HTS could be identified in the literature. Although, 
importantly, Yumanity Therapeutics (co-founded by Susan Linquist [18, 19, 20]) have very 
recently (September 2018) issued a press release reporting the first clinical candidate (YTX-
7739) for Parkinson’s disease discovered through their proprietary integrated discovery 
platform which includes a yeast-based component. Furthermore, very recent work has 
demonstrated the tractability of these HTS systems for screening hard to purify/assay proteins 
(e.g. transmembrane enzymes involved in lipid biosynthesis) in a robust miniaturized (1536-
well) platform against a 1.8 million compound library [41]. This demonstrated that yeast-based 
platforms have huge potential to be deployed in industrial drug discovery, for the reasons cited 
above coupled with the fact that these rapidly growing, simple eukaryotes are cheap and easy 
  
to cultivate and manipulate. To fully exploit the opportunities yeast-based HTS provides a 
number of challenges need to be addressed. Whilst 1536-well ultra-HTS has been reported 
[41], the fluorescent signal measured relied upon the addition of an expensive external agent 
(FDGlu) which required additional buffering [41]. The use of fluorescent proteins (either tagged 
target or expressed independently) has been reported and used to multiplex yeast-based HTS 
platforms [36, 37, 38]. This has great potential advantages, however the differential 
fluorescence seen in cell population expressing these proteins from the transformed plasmid 
[37] would prove problematic in any effort to achieve ultra-HTS. Indeed, in our ultra-HTS efforts 
[41] we abandoned this approach (Mina and Denny, unpublished). The use of clonal, stable 
yeast cell lines with integrated fluorescent markers should overcome this limitation and open 
the door for multiplexed ultra-HTS which would allow the selection of target specific 
compounds in a relatively cheap and efficient manner. 
Therefore, whilst the future is difficult to predict, yeast-based platforms are well positioned to 
take their place in the armoury of drug discovery techniques in coming years, alongside 
conventional in vitro biochemical and phenotypic approaches, and fragment-based [52] and 
virtual screening [53, 54]. Whilst this may well happen out of sight of the academic community, 
such an increase in activity will increase the probability of compound hits entering hit to lead 
and preclinical trials programmes. 
 
Article Highlights Box: 
• Yeast-based screening has the potential to bridge the gap between phenotypic and 
biochemical assays for HTS 
• Lethal expression, transactivation and substitution yeast-based assays have all been 
effectively employed in HTS, including ultra HTS 
• Exploiting the genetic tractability of yeast to overcome platform limitations is possible, 
e.g. deletion of efflux pumps and use of fluorescent markers for multiplexing 
• Recent developments, including the identification of a clinical candidate for Parkinson’s 
disease, have shown that yeast-based HTS can take its place amongst the currently 
utilized drug discovery platforms 
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Figures and tables: 
 
Table 1 
 Advantages Disadvantages 
In vitro HTS Possibility of simple, specific and 
sensitive assay system 
Facilitates SAR based on 
molecular recognition of the target 
 
Requires purified target, limiting 
assay of hard to purify/assay targets 
such as transmembrane enzymes 
Expensive due to necessity for protein 
purification etc 
Requirement for suitable substrates 
Phenotypic HTS Does not require purified target 
Provides specific cellular context 
allowing early selection of drug-
like compounds 
Naïve approach challenging all 
targets at once in an unbiased 
manner 
Relatively insensitive due to drug 
pumps and membrane barriers 
Expensive or inability to culture 
relevant cell type 
Reliance on non-target specific, 
phenotypic output 
SAR is not assisted by target 
knowledge. Target deconvolution is 
approached a posteriori 
Yeast-based HTS Does not require purified target 
Provides axenic eukaryotic 
cellular context allowing early 
selection of drug-like compounds 
Ease of manipulation and speed 
of growth 
Straightforward genetic 
manipulation for generic assay 
platforms 
Ease of discrimination of false 
positive hits 
Low cost of culture 
Relatively insensitive due to drug 
pumps, membrane barriers and the 
thick cell wall 
Often reliant on the ability of an 
heterologous protein to be functional 
in an axenic system 
Target protein is tested in a non-
native cellular milieu 
 
 
 
 
Table 2
  
Organism Disease/effect Target(s) Assay Library/hits Outcome Reference 
Influenza virus Influenza Ion-channel 
forming M2 
Lethal expression 
in Saccharmoyces 
cerevisiae, 96-well 
plates 
‘Compounds drawn from the 
Bristol-Myers Squibb compound 
collection’,  
1 hit 
 
In vivo activity in plaque assay 
(µM) 
Kurtz et al, 
1995 [12] 
Haemonchus 
contortus  
Anaemia and oedema 
in ruminants 
Orthithine 
decarboxylase 
Substitution in S. 
cerevisiae, 96-well 
plates 
‘A subset of a collection of 
synthetic compounds’, (90,000),  
1 hit 
Single hit shown to be not on 
target in vitro and in cellulo 
Klein et al, 
1997 [35] 
Human Neurological trauma Calcium channel 
(subunits a1B and 
b3) 
Transactivation (2 
hybrid) in S. 
cerevisiae, agar 
plates 
Subset American Home Products 
Corporate (156,000), 10 hits 
Specific in cellulo activity (µM) Young et al, 
1998 [49] 
Human Cancer, diabetes, 
cardiovascular 
diseases, neuro-
degenerative diseases 
 
Sirtuin (SIRT2) Transactivation in 
S. cerevisiae, 96- 
and 384-well plates 
IICB Diversity and Chem-Bridge 
(1,600), 3 hits 
Specific in vitro, in cellulo 
(mammalian) and in vivo 
(plant) activity (µM) 
Grozinger et 
al, 20014 
 [22] 
Human Prion diseases Prion protein (PrP) Lethal expression 
in S. cerevisiae, 
agar plates 
‘Synthetic and natural products 
purified from various sources by 
academic laboratories’ (2,500), 6 
hits 
Specific in cellulo activity in 
yeast and mammalian systems 
(µM) 
Bach et al, 
2003 [46], 
2006 [47] 
Human Alzheimer’s disease b-secretase Transactivation in 
S. cerevisiae, 96-
well plates 
‘Chemical compound library’ 
(15,000), 13 hits 
Specific in cellulo activity (µM)  Middendorp 
et al, 2004 
[23] 
Human Inflammatory diseases, 
cancer, congestive 
heart disease 
protein kinase 
p38a 
 
Lethal expression 
in S. cerevisiae, 96-
well plates 
ChemDiv combinatorial (40,000), 
2 hits 
On target in vitro and in cellulo 
activity (nM-µM) 
Freidmann 
et al, 2006 
[17] 
Human Parkinson’s disease a-synuclein  
(a-syn) 
Lethal expression 
in S. cerevisiae, 
agar, 96- and 384-
well plates  
‘collection of 10,022 diverse 
compounds’ from ComGenex 
and Sigma Aldrich 
 
Expressed cyclic peptide library 
(5M) 
 
‘Over 115,000 compounds from 
various collections, including 
commercial libraries, natural 
products and National Cancer 
Institute collections’  
Active flavonoids identified 
 
 
 
Specific in cellulo activity in 
nematode model system (µM) 
 
Specific in cellulo activity in 
nematode and mammalian 
model systems (µM) 
 
Griffioen et 
al, 2006 [18] 
 
 
Kritzer et al, 
2009 [19] 
 
Su et al, 
2010 [20] 
 
 
  
Human Neurological dis- eases, 
inflammatory diseases, 
metabolic diseases, 
memory loss, cancer, 
erectile dysfunction  
 
Phosphodiesterase 
(PDE) 2A/4A/4B/8 
 
 
PDE7 
 
 
PDE11 
 
 
 
PDE4/8 
 
 
 
 
 
 
 
 
PDE 4/7 
Transactivation in 
S. pombe, 384-well 
plates 
‘Subset’ Prestwick Bioactive & 
Microsource Spectrum (3120), 
151 hits 
 
‘Commercial chemical libraries’, 
(48,176), 5 hits 
 
Including Actimol TimTec1, 
ChemBridge1,3, ChemDiv3&6  
(198,382), 39 hits 
 
BIOMOL2 ICCB,  
Prestwick1, NINDS2, Asinex1, 
Biomol-TimTec1, Bionet1-2, 
CEREP, ChemBridge3, ChemDiv 
1-4&6, Enamine1-2, I.F. Lab2, 
Life Chemicals1, MayBridge1-5, 
MixCommercial1-3&5, and 
Peakdale (222,711), 367 hits 
 
Broad Institute (undefined), 163-
1610 hits 
 
On target (PDE4B) in cellulo 
activity (µM) 
 
 
On target in cellulo and in vitro 
activity (µM) 
 
On target in cellulo and in vitro 
activity (µM) 
 
 
On target in vitro activity (nM) 
and elevation of cell 
testosterone and progesterone 
in cellulo (µM) 
 
 
 
 
 
On target in vitro activity (nM), 
anti-inflammatory action in 
cellulo (µM) and molecular 
docking (low energy) 
Ivey et al, 
2008 [28] 
 
 
Alaamery et 
al, 2010 [24] 
 
Cayhan et 
al, 2011[25] 
 
 
 
Demirbas et 
al, 2013 [27] 
 
 
 
 
 
 
Santos de 
Medeiros et 
al, 2017 [26] 
Human Anderson sydrome Potassium channel 
(Kir2.1) 
Substitution in S. 
cerevisiae, 96-well 
plates 
MicroSource Natural Products 
Library (720), 
1 hit 
On target in cellulo activity in 
yeast and mammalian cells 
(µM) 
Zaks-
Makhina et 
al, 2009 [32] 
Human Obesity, cancer Acetyl-CoA 
carboxylase 1/2 
(ACC1/2)  
Substitution in S. 
cerevisiae, 96-well 
plates 
ChemDiv:  ‘ACC1 Structure-
Activity Relationship Library’ 
(3,068); ‘Diverse screening 
library’ (30,000); ‘ACC2 Analog 
Screening Library’ (828), 38 hits 
On target in vitro activity 
selective for AAC2 (µM) 
Marjanovic 
et al, 2010 
[33] 
HIV-1 AIDS Viral protein R  
 
Lethal expression 
in Saccharmoyces 
pombe, 384-well 
and agar plates 
Microsource Spectrum Collection 
(2,000), 1 hit  
Confirmation of anti-apoptotic 
effect (µM) 
Benko et al, 
2010 [13] 
Human Mitochondrial disease Mitochondrial ATP 
synthase (ATP6) 
Lethal expression 
in S. cerevisiae, 
agar plates 
‘Compounds from various 
chemical libraries’ (12,000), 10 
hits 
On target in cellulo activity in 
mammalian cells (µM) 
Couplan et 
al, 2011 [48] 
Human Cancer,  autoimmune  
diseases, metabolic 
disorders,  
atherosclerosis 
cardiovascular disease  
Phosphatidyl-
inositol 3-kinase 
(PI3K)  
 
Lethal expression 
in Saccharmoyces 
cerevisiae, 96-well 
plates 
‘Collection of natural products of 
microbial origin’ (9,600), 
55 hits 
 
On target in cellulo (µM) Fernandez-
Acero et al, 
2012 [16] 
  
 
Plasmodium 
spp, 
Schistosoma 
masoni, 
Trypanosoma 
spp, 
Leishmania 
major 
Malaria 
 
Schistosomiasis 
 
African/American 
trypanosomaisis 
 
Leishmaniasis 
Dihydrofolate 
reductase (DHFR), 
N-myristoyl-
transferase (NMT), 
Phosphoglycerate 
kinase (PGK)  
 
Substitution in S. 
cerevisiae, 
multiplexed, 384-
well plates 
Maybridge Hitfinder (14,400), 
445 hits 
 
Anti-T. brucei activity in cellulo 
(nM) 
Bilsland et 
al, 2013 [37] 
Human Cancer, diabetes, 
cardiovascular 
disease, obesity, 
male contraception 
Adenine Nucleotide 
Translocase 4 (ANT4)  
Substitution in S. 
cerevisiae, 384-well 
plates 
65,000 compounds from 
‘commercial sources’, 
19 hits 
On target activity in vitro (µM) Zhang et al, 
2016 [34] 
P. falciparum Malaria Nucleoside 
Transporter 1  
Substitution in S. 
cerevisiae, 384-well 
plates 
‘several chemical libraries’ 
(64,560), 171 hits 
On target cellular activity (nM) 
and anti-parasitic activity 
against infected erythrocytes 
(µM) 
Frame et al, 
2015 [21] 
Brugia malayi Lymphatic filariasis  
 
NMT, PGK, triose-
phosphate 
isomerase, adenosyl 
homocysteinase, 
thymidylate 
synthetase, ribose-5-
phosphate 
isomerase, 
deoxyhypusine 
synthase, CDP-
alcohol phosphatidyl 
transferase 
Substitution in S. 
cerevisiae, 
multiplexed, 384-
well plates 
Malaria Box (400), 9 hits Anti-B. malayi activity in cellulo 
(µM) 
Bilsland et 
al, 2016 [36] 
Leishmania 
spp 
Leishmaniasis Inositol phosphoryl-
ceramide (IPC) 
synthase  
Substitution in S. 
cerevisiae, 1536-
well plates 
GSK library (1.8M), 500 hits On target in vitro and in cellulo 
activity (nM-µM) and anti-
leishmanial activity in cellulo 
(nM) 
Norcliffe et 
al, 2018 [41] 
Plasmodium 
spp 
Malaria DHFR Substitution in S. 
cerevisiae, 
multiplexed, 384-
well plates.  
Johns Hopkins FDA & foreign 
approved library (1,600),1 hit  
On target in vitro (nM), anti-P. 
falciparum activity in cellulo 
(µM) and molecular docking 
(low energy) 
Bilsland et 
al, 2018 [38] 
 
 
 
 
